# FOLFIRINOX + RT for Pancreatic Cancer

> **NCT01591733** · PHASE2 · UNKNOWN · sponsor: **Massachusetts General Hospital** · enrollment: 48 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** FOLFIRINOX
- **DRUG:** Capecitabine
- **RADIATION:** Short Course Radiation
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT01591733
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-05
- **Primary completion:** 2017-03
- **Final completion:** 2022-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2021-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01591733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01591733, "FOLFIRINOX + RT for Pancreatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01591733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*